by Elizabeth Hlavinka: For More Info, Go Here…
Non-selective beta-adrenergic blockade was linked to improved outcomes for patients with a common form of pancreatic cancer, according to a retrospective analysis presented here.
In a sample of more than 1,000 patients with pancreatic adenocarcinoma, those on non-selective beta blockers showed significantly decreased perineural invasion compared to patients on beta-1 selective blockade and those with no documented beta-blockers (68% vs 85% vs 86%, P<0.001), reported Alex Blair, MD, of Johns Hopkins Hospital in Baltimore, and colleagues.
Median overall survival was also significantly longer among patients taking non-selective beta blockers compared with those on beta-1 selective blockers or not taking any beta-blockade (26.1 months vs 18.5/18.8 months, respectively; P=0.007), he said here at the annual Digestive Disease Week.
“These data are further evidence that support the popular repurposing of commonly used medications as anti-cancer therapeutic adjuncts,” Blair said while presenting his findings.
